Literature DB >> 31498104

Drug interactions: not just for orally administered drugs.

Catherine A Chappell1, Sharon L Achilles2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31498104      PMCID： PMC7262782          DOI： 10.1016/S2352-3018(19)30185-7

Source DB:  PubMed          Journal:  Lancet HIV        ISSN： 2352-3018            Impact factor:   12.767


× No keyword cloud information.
  8 in total

1.  The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women.

Authors:  Heather Sevinsky; Timothy Eley; Anna Persson; Dennis Garner; Cynthia Yones; Richard Nettles; Kathryn Krantz; Richard Bertz; Jenny Zhang
Journal:  Antivir Ther       Date:  2011

2.  Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy.

Authors:  Catherine A Chappell; Mohammed Lamorde; Shadia Nakalema; Beatrice A Chen; Hope Mackline; Sharon A Riddler; Susan E Cohn; Kristin M Darin; Sharon L Achilles; Kimberly K Scarsi
Journal:  AIDS       Date:  2017-09-10       Impact factor: 4.177

3.  Influence of Genetic Variants on Steady-State Etonogestrel Concentrations Among Contraceptive Implant Users.

Authors:  Aaron Lazorwitz; Christina L Aquilante; Kris Oreschak; Jeanelle Sheeder; Maryam Guiahi; Stephanie Teal
Journal:  Obstet Gynecol       Date:  2019-04       Impact factor: 7.661

4.  Contraception to prevent HIV-positive births: current contribution and potential cost savings in PEPFAR countries.

Authors:  H W Reynolds; B Janowitz; R Wilcher; W Cates
Journal:  Sex Transm Infect       Date:  2008-10       Impact factor: 3.519

5.  The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine.

Authors:  M Neary; M Lamorde; A Olagunju; K M Darin; C Merry; P Byakika-Kibwika; D J Back; M Siccardi; A Owen; K K Scarsi
Journal:  Clin Pharmacol Ther       Date:  2017-05-30       Impact factor: 6.875

6.  Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and Efavirenz.

Authors:  Monica L Carten; Jennifer J Kiser; Awewura Kwara; Samantha Mawhinney; Susan Cu-Uvin
Journal:  Infect Dis Obstet Gynecol       Date:  2012-02-28

7.  Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.

Authors:  Andrea Ries Thurman; Jill L Schwartz; Vivian Brache; Meredith R Clark; Timothy McCormick; Neelima Chandra; Mark A Marzinke; Frank Z Stanczyk; Charlene S Dezzutti; Sharon L Hillier; Betsy C Herold; Raina Fichorova; Susana N Asin; Christiane Rollenhagen; Debra Weiner; Patrick Kiser; Gustavo F Doncel
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

8.  Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks.

Authors:  Kimberly K Scarsi; Kristin M Darin; Shadia Nakalema; David J Back; Pauline Byakika-Kibwika; Laura J Else; Sujan Dilly Penchala; Allan Buzibye; Susan E Cohn; Concepta Merry; Mohammed Lamorde
Journal:  Clin Infect Dis       Date:  2015-12-08       Impact factor: 9.079
  8 in total
  1 in total

1.  PITCHing ursodeoxycholic acid in intrahepatic cholestasis of pregnancy versus placebo.

Authors:  Katrina Ray
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-10       Impact factor: 46.802
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.